The journey of a drug-carrier in the body: An anatomo-physiological perspective

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 152-163

  Bertrand, Nicolas ^a   Leroux, Jean Christophe ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ETH ZURICH   (Switzerland)

Author keywords

Accelerated blood clearance; Complement system; Drug delivery; Mononuclear phagocyte system; Nanomedicine; Nanoparticles

Indexed keywords

ACCELERATED BLOOD CLEARANCES; CLINICAL DEVELOPMENT; COLLOIDAL DRUG CARRIERS; COMPLEMENT SYSTEMS; DRUG-TARGETING; EFFICIENT SYSTEMS; IMAGING AGENT; MATERIAL SCIENCE; MONONUCLEAR PHAGOCYTE SYSTEMS; NANO-SIZED; NANOMATERIAL; NANOSIZED MATERIALS; RESEARCH AND DEVELOPMENT;

DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

PHYSIOLOGY;

ALBUMIN; APOLIPOPROTEIN; DRUG CARRIER; DYSOPSONIN; LIPOPROTEIN; OPSONIN; PLASMA PROTEIN; UNCLASSIFIED DRUG;

BILIARY EXCRETION; BLOOD CELL; COMPLEMENT ACTIVATION; DRUG TARGETING; GLOMERULUS FILTRATION; HUMAN; KIDNEY TUBULE ABSORPTION; KUPFFER CELL; LIVER; MORPHOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SPLEEN; SYSTEMIC CIRCULATION;

ANIMALS; DRUG CARRIERS; HUMANS; KIDNEY; LIVER; SPLEEN;

EID: 84859510563     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.098     Document Type: Review

References (190)

1. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol. 2 (2007) 751-760.
2. K. Kostarelos, A. Bianco, M. Prato, Promises, facts and challenges for carbon nanotubes in imaging and therapeutics, Nat. Nanotechnol. 4 (2009) 627-633.
3. D. Ho, Beyond the sparkle: the impact of nanodiamonds as biolabeling and therapeutic agents, ACS Nano 3 (2009) 3825-3829.
4. S.E. Skrabalak, J. Chen, Y. Sun, X. Lu, L. Au, C.M. Cobley, Y. Xia, Gold nanocages: synthesis, properties and applications, Acc. Chem. Res. 41 (2008) 1587-1595.
5. N. Doshi, A. Zahr, S. Bhaskar, J. Lahann, S. Mitragotri, Red blood cell-mimicking synthetic biomaterials particles, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 21495-21499.
6. A.E. Nel, L. Mädler, D. Velegol, T. Xia, E.M.V. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, M. Thompson, Understanding biophysicochemical interactions at the nano-bio interface, Nat. Mater. 8 (2009) 543-557.
7. V.P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discovery 4 (2005) 145-160.
8. G. Gaucher, M.-H. Dufresne, V.P. Sant, N. Kang, D. Maysinger, J.C. Leroux, Block copolymer micelles: preparation, characterization and application in drug delivery, J. Control. Release 109 (2005) 169-188.
9. R.K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol. 7 (2010) 653-664.
10. D.A. Scheinberg, C.H. Villa, F.E. Escorcia, M.R. McDevitt, Conscripts of the infinite armada: systemic cancer therapy using nanomaterials, Nat. Rev. Clin. Oncol. 7 (2010) 266-276.
11. N. Bertrand, C. Bouvet, P. Moreau, J.C. Leroux, Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication, ACS Nano 4 (2010) 7552-7558.
12. J.C. Leroux, Injectable nanocarriers for biodetoxification, Nat. Nanotechnol. 2 (2007) 679-684.
13. K.A. Whitehead, R.S. Langer, D.G. Anderson, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discovery 8 (2009) 129-138.
14. M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A.W. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature 464 (2010) 1067-1070.
15. O.C. Farokhzad, R. Langer, Impact of nanotechnology on drug delivery, ACS Nano 3 (2009) 16-20.
16. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer 6 (2006) 688-701.
17. C.C. Lee, J.A. MacKay, J.M.J. Fréchet, F.C. Szoka, Designing dendrimers for biological applications, Nat. Biotechnol. 23 (2005) 1517-1526.
18. N. Bertrand, M.A. Gauthier, C. Bouvet, P. Moreau, A. Petitjean, J.C. Leroux, J. Leblond, New pharmaceutical applications for macromolecular binders, J. Control. Release (2011) [Electronic publication ahead of print, May 5], doi:10.1016/j.jconrel.2011.04.027.
19. H.S. Choi, Y. Ashitate, J.H. Lee, S.H. Kim, A. Matsui, N. Insin, M.G. Bawendi, M. Semmler-Behnke, J.V. Frangioni, A. Tsuda, Rapid translocation of nanoparticles from the lung airspaces to the body, Nat. Biotechnol. 28 (2010) 1300-1303.
20. B.E. Rabinow, Nanosuspensions in drug delivery, Nat. Rev. Drug Discovery 3 (2004) 785-796.
21. C.M. Doerschuk, N. Beyers, H.O. Coxson, B. Wiggs, J.C. Hogg, Comparison of neutrophil and capillary diameters and their relation to neutrophil sequestration in the lung, J. Appl. Physiol. 74 (1993) 3040-3045.
22. H.L. Kutscher, P. Chao, M. Deshmukh, Y. Singh, P. Hu, L. Joseph, D.C. Reimer, S. Stein, D.L. Laskin, P.J. Sinko, Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats, J. Control. Release 143 (2010) 31-37.
23. N. Bertrand, J.G. Fleischer, K.M. Wasan, J.C. Leroux, Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes, Biomaterials 30 (2009) 2598-2605.
24. P. Chollet, M.C. Favrot, A. Hurbin, J.L. Coll, Side-effects of a systemic injection of linear polyethylenimine-DNA complexes, J. Gene Med. 4 (2002) 84-91.
25. B. Davies, T. Morris, Physiological parameters in laboratory animals and humans, Pharm. Res. 10 (1993) 1093-1095.
26. M.J. Hickey, P. Kubes, Intravascular immunity: the host-pathogen encounter in blood vessels, Nat. Rev. Immunol. 9 (2009) 364-375.
27. S. Gordon, P.R. Taylor, Monocyte and macrophage heterogeneity, Nat. Rev. Immunol. 5 (2005) 953-964.
28. V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D.S. Weiss, Y. Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria, Science 303 (2004) 1532-1535.
29. T.A. Fuchs, A. Brill, D. Duerschmied, D. Schatzberg, M. Monestier, D.D. Myers, S. Wrobleski, T.W. Wakefield, J.H. Hartwig, D.D. Wagner, Extracellular DNA traps promote thrombosis, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 15880-15885.
30. S.R. Clark, A.C. Ma, S.A. Tavener, B. McDonald, Z. Goodarzi, M.M. Kelly, K.D. Patel, S. Chakrabarti, E. McAvoy, G.D. Sinclair, E.M. Keys, E. Allen-Vercoe, R. DeVinney, C.J. Doig, F.H. Green, P. Kubes, Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood, Nat. Med. 13 (2007) 463-469.
31. M. Bartneck, H.A. Keul, G. Zwadlo-Klarwasser, J. Groll, Phagocytosis independent extracellular nanoparticles clearance by human immune cells, Nano Lett. 10 (2010) 59-63.
32. M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, K.A. Dawson, Nanoparticle size and surface properties determined the protein corona with possible implications for biological impacts, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14265-14270.
33. D.E. Owens III, N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 307 (2006) 93-102.
34. S.C. Semple, A. Chonn, P.R. Cullis, Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo, Adv. Drug Delivery Rev. 32 (1998) 3-17.
35. S.M. Moghimi, A.C. Hunter, J.C. Murray, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev. 53 (2001) 283-318.
36. J.T. Anderson, I. Sandlie, The versatile MHC Class 1-related FcRn protects IgG and albumin from degradation: implications for the development of new diagnostics and therapeutics, Drug Metab. Pharmacokinet. 24 (2009) 318-332.
37. T. Blunk, A. Calvör, D. Hochstrasser, J. Sancher, B. Müller, R.H. Müller, Kinetics of plasma adsorption on model particles for controlled drug delivery and drug targeting, Eur. J. Pharm. Biopharm. 42 (1996) 262-268.
38. G. Gaucher, K. Asahina, J. Wang, J.-C. Leroux, Effect of poly(N-vinyl-pyrrolidone)-block-poly(D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles, Biomacromolecules 10 (2009) 408-416.
39. C. Röcker, M. Pötzl, F. Zhang, W.J. Parak, G.U. Nienhaus, A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles, Nat. Nanotechnol. 4 (2009) 577-580.
40. É. Alléman, P. Gravel, J.C. Leroux, L. Balant, R. Gurny, Kinetics of blood component adsorption on poly(D, L-lactic acid) nanoparticles: evidence of complement C3 component involvement, J. Biomed. Mater. Res. 37 (1997) 229-234.
41. K.-i. Ogawara, K. Furumoto, S. Nagayama, K. Minato, K. Higaki, T. Kai, T. Kimura, Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles, J. Control. Release 100 (2004) 451-455.
42. F. Kratz, Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles, J. Control. Release 132 (2008) 171-183.
43. G. Hartnung, G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, S. Heeger, M. Kränzle, L. Edler, E. Frei, H.H. Fiebig, D.L. Heene, W. Maier-Borst, W. Queisser, Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients, Clin. Cancer Res. 5 (1999) 753-759.
44. C.E. Dumelin, S. Trussel, F. Buller, E. Trachsel, F. Bootz, Y. Zhang, L. Mannocci, S.C. Beck, M. Drumea-Mirancea, M.W. Seeliger, C. Baltes, T. Muggler, F. Kranz, M. Rudin, S. Melkko, J. Scheuermann, D. Neri, A portable albumin binder from a DNA-encoded chemical library, Angew. Chem. Int. Ed. 47 (2008) 3196-3201.
45. J. Cortes, C. Saura, Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer, Eur. J. Cancer Suppl 8 (2010) 1-10.
46. N.P. Desai, V. Trieu, B. Damascelli, P. Soon-Shiong, SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients, Transl. Oncol. 2 (2009) 59-64.
47. N.P. Desai, V. Trieu, L.Y. Hwang, R. Wu, P. Soon-Shiong, W.J. Gradishar, Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a a function of HER2 and SPARC status, Anticancer Drugs 19 (2008) 899-909.
48. K.M. Wasan, D.R. Brocks, S.D. Lee, K. Sachs-Barrable, S.J. Thornton, Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery, Nat. Rev. Drug Discovery 7 (2008) 84-99.
49. W.V. Rodrigueza, M.C. Phillips, K.J. Williams, Structural and metabolic consequences of liposome-lipoprotein interactions, Adv. Drug Delivery Rev. 32 (1998) 31-43.
50. T.M. Allen, A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles, Biochim. Biophys. Acta 640 (1981) 385-397.
51. T. Cedervall, I. Lynch, M. Foy, T. Berggard, S.C. Donnelly, G. Cagney, S. Linse, K.A. Dawson, Detailed identification of plasma proteins adsorbed on copolymer nanoparticles, Angew. Chem. Int. Ed Engl. 119 (2007) 5856-5858.
52. A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K.N. Jayaprakash, M. Jayaraman, K.G. Rajeev, W.L. Cantley, J.R. Dorkin, J.S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M.J. Hope, M. Zerial, D.W.Y. Sah, K. Fitzgerald, M.A. Tracy, M. Manoharan, V. Koteliansky, A.R. de Fougerolles, M.A. Maier, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol. Ther. 18 (2010) 1357-1364.
53. P.C. Rensen, M.C. Van Dijk, E.C. Havenaa, M.K. Bijsterbosch, J. Kar Krujit, T.J.C. Van Berkel, Selective liver targeting of antivirals by recombinant chylomicrons: a new therapeutic approach to hepatitis B, Nat. Med. 1 (1995) 221-225.
54. J. Kreuter, T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, K. Langer, Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain, J. Control. Release 118 (2007) 54-58.
55. C. Wolfrum, S. Shi, K.N. Jayaprakash, M. Jayaraman, G. Wang, R.K. Pandey, K.G. Rajeev, T. Nakayama, K. Charrise, E.M. Ndungo, T. Zimmermann, V. Koteliansky, M. Manoharan, M. Stoffel, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat. Biotechnol. 25 (2007) 1149-1157.
56. D. Ricklin, G. Hajishengallis, K. Yang, J.D. Lambris, Complement: a key system for immune surveillance and homeostasis, Nat. Immunol. 11 (2010) 785-797.
57. M.J. Walport, Advances in immunology: complement: first of two parts, N. Engl. J. Med. 344 (2001) 1058-1066.
58. P.F. Zipfel, C. Skerka, Complement regulator and inhibitory proteins, Nat. Rev. Immunol. 9 (2009) 729-740.
59. J. Szebeni, Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity, Toxicology 216 (2005) 106-121.
60. D.V. Devine, K. Wong, K. Serrano, A. Chonn, P.R. Cullis, Liposome-complement interactions in rat serum: implications for liposome survival studies, Biochim. Biophys. Acta 1191 (1994) 43-51.
61. A. Gessner, R. Waicz, A. Lieske, B. Paulke, K. Mäder, R.H. Müller, Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption, Int. J. Pharm. 196 (2000) 245-249.
62. S.C. Semple, A. Chonn, P.R. Cullis, Influence of cholesterol on the association of plasma proteins with liposomes, Biochemistry 35 (1996) 2521-2525.
63. A. Chonn, P.R. Cullis, D.V. Devine, The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes, J. Immunol. 146 (1991) 4234-4241.
64. H. Harashima, K. Sakata, K. Funato, H. Kiwada, Enhanced hepatic uptake of liposomes through complement activation depending on the size of the liposomes, Pharm. Res. 11 (1994) 402-406.
65. A. Vonarbourg, C. Passirani, P. Saulnier, P. Simard, J.C. Leroux, J.-P. Benoit, Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake, J. Biomed. Mater. Res. 78A (2006) 620-628.
66. I. Hamad, O. Al-Hanbali, A.C. Hunter, K.J. Rutt, T.L. Andresen, S.M. Moghimi, Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering, ACS Nano 11 (2010) 6629-6638.
67. S.M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid. Res. 42 (2003) 463-478.
68. A. Vonarbourg, C. Passirani, P. Saulnier, J.-P. Benoit, Parameters influencing the stealthiness of colloidal drug delivery systems, Biomaterials 27 (2006) 4356-4373.
69. K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed Engl. 49 (2010) 6288-6308.
70. M.J. Harris, R.B. Chess, Effect of pegylation of pharmaceuticals, Nat. Rev. Drug Discovery 2 (2003) 214-221.
71. S.M. Moghimi, A. Andersen, S. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, T. Andresen, I. Hamad, J. Szebeni, Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead, J. Control. Release 146 (2010) 175-181.
72. I. Hamad, A.C. Hunter, K.J. Rutt, Z. Liu, H. Dai, S.M. Moghimi, Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover, Mol. Immunol. 45 (2008) 3797-3803.
73. S.M. Moghimi, I. Hamad, T.L. Andresen, K. Jorgensen, J. Szebeni, Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production, FASEB J. 20 (2006) E2057-E2067.
74. A. Chahan-Khan, J. Szebeni, S. Savay, L. Liebes, N. Rafique, C.R. Alving, F. Muggia, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil(R)): possible role in hypersensitivity reactions, Ann. Oncol. 14 (2003) 1430-1437.
75. I. Hamad, A.C. Hunter, J. Szebeni, S.M. Moghimi, Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process, Mol. Immunol. 46 (2008) 225-232.
76. S.M. Moghimi, A.C. Hunter, C.M. Dadswell, S. Savay, C.R. Alving, J. Szebeni, Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels, Biochim. Biophys. Acta 1689 (2004) 103-113.
77. S.T. Reddy, A.J. van der Vlies, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O'Neil, L.K. Lee, M.A. Swartz, J.A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticles vaccines, Nat. Biotechnol. 25 (2007) 1159-1164.
78. M.R. Ehrenstein, C.A. Notley, The importance of natural IgM: scavenger, protector and regulator, Nat. Rev. Immunol. 10 (2010) 778-786.
79. M.A. Dobrovolskaia, S.E. McNeil, Immunological properties of engineered nanomaterials, Nat. Nanotechnol. 2 (2007) 469-478.
80. J.A. Hubbell, S.A. Thomas, M.A. Swartz, Materials engineering for immunomodulation, Nature 462 (2009) 449-460.
81. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, S.E. McNeil, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv. Drug Delivery Rev. 61 (2009) 428-437.
82. H. Chen, S. Kim, W. He, H.-f. Wang, P.S. Low, K. Park, J.-X. Cheng, Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Förster resonance energy transfer imaging, Langmuir 24 (2008) 5213-5217.
83. H. Chen, S. Kim, L. Li, S. Wang, K. Park, J.-X. Cheng, Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6596-6601.
84. G. Girardi, P. Redecha, J.E. Salmon, Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, Nat. Med. 10 (2004) 1222-1226.
85. J.C. Leroux, F. De Jaeghere, B. Anner, E. Doekler, R. Gurny, An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D, L-lactic acid) nanoparticles by human monocytes, Life Sci. 57 (1995) 695-703.
86. B. Haraldsson, J. Nyström, W.M. Deen, Properties of the glomerular barrier and mechanisms of proteinuria, Physiol. Rev. 88 (2008) 451-487.
87. A.F. Michael, W.F. Keane, L. Raij, R.L. Vernier, S.M. Mauer, Glomerular mesangium, Kidney Int. 17 (1980) 141-154.
88. T. Maack, V. Johnson, S.T. Kau, J. Figueiredo, D. Sigulem, Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review, Kidney Int. 16 (1979) 251-270.
89. J. Kopecek, P. Kopeckova-Rejmanova, T. Minko, Z.-R. Lu, C.M. Peterson, Water soluble polymers in tumor targeted delivery, J. Control. Release 74 (2001) 147-158.
90. W. Gao, W. Liu, T. Christensen, M.R. Zalutsky, A. Chilkoti, In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 16432-16437.
91. L.W. Seymour, R. Duncan, J. Strohalm, J. Kopecek, Effect of Molecular Weight (Mw) on N(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats, J. Biomed. Mater. Res. 21 (1987) 1341-1358.
92. C. Li, J.E. Price, L. Milas, N.R. Hunter, S. Ke, D.-F. Yu, C. Charnsangavej, S. Wallace, Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors, Clin. Cancer Res. 5 (1999) 891-897.
93. M.A. Gauthier, H.-A. Klok, Polymer-protein conjugates: an enzymatic activity perspective, Polym. Chem. 1 (2010) 1352-1373.
94. V. Schellenberger, C.-w. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To, M.D. Scholle, Y. Yin, Y. Tao, O. Bogin, J.L. Cleland, J. Silverman, W.P. Stemmer, A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner, Nat. Biotechnol. 27 (2009) 1186-1191.
95. J. Zalevsky, A.K. Chamberlain, H.M. Horton, S. Karki, I.W. Leung, T.J. Sproule, G.A. Lazar, D.C. Roopenian, J.R. Desjarlais, Enhanced antibody half-life improve in vivo activity, Nat. Biotechnol. 28 (2010) 157-159.
96. M.E. Fox, F.C. Szoka, J.M.J. Fréchet, Soluble polymer carriers for the treatment of cancer: the importance of the molecular architecture, Acc. Chem. Res. 42 (2009) 1141-1151.
97. N. Nasongkla, B. Chen, N. Macaraeg, M.E. Fox, J.M.J. Fréchet, F.C. Szoka, Dependence of pharmacokinetics and biodistriubtion on polymer architecture: effect of cyclic versus linear polymers, J. Am. Chem. Soc. 131 (2009) 3842-3843.
98. T. Yamaoka, Y. Tabata, Y. Ikada, Body distribution profile of polysaccharides after intravenous administration, Drug Deliv. 1 (1993) 75-82.
99. T. Yamaoka, Y. Tabata, Y. Ikada, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice, J. Pharm. Sci. 83 (1994) 601-606.
100. T. Yamaoka, Y. Tabata, Y. Ikada, Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration, J. Pharm. Pharmacol. 47 (1995) 479-486.
101. T. Yamaoka, Y. Tabata, Y. Ikada, Body distribution of intravenously administered gelatin with different molecular weights, J. Control. Release 31 (1994) 1-8.
102. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B.I. Ipe, M.G. Bawendi, J.V. Frangioni, Renal clearance of nanoparticles, Nat. Biotechnol. 25 (2007) 1165-1170.
103. H.S. Choi, W. Liu, F. Liu, K. Nasr, P. Misra, M.G. Bawendi, J.V. Frangioni, Design considerations for tumour-targeted nanoparticles, Nat. Nanotechnol. 5 (2010) 42-47.
104. M.L. Schipper, N. Nakayama-Ratchford, C.R. Davis, N.W.S. Kam, P. Chu, Z. Liu, X. Sun, H. Dai, S.S. Gambhir, A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice, Nat. Nanotechnol. 3 (2008) 216-221.
105. Z. Liu, C. Davis, W. Cai, L. He, X. Chen, H. Dai, Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1410-1415.
106. A. Ruggiero, C.H. Villa, E. Bander, D.A. Rey, M. Bergkvist, C.A. Batt, K. Manova-Todorova, W.M. Deen, D.A. Scheinberg, M.R. McDevitt, Paradoxical glomerular filtration of carbon nanotubes, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 12369-12374.
107. L. Lacerda, M.A. Herrero, K. Venner, A. Bianco, M. Prato, K. Kostarelos, Carbon-nanotube shape and individualization critical for renal excretion, Small 4 (2008) 1130-1132.
108. K. Kostarelos, L. Lacerda, G. Pastorin, W. Wu, S. Wieckowski, J. Luangsivilay, S. Godefroy, D. Pantarotto, J.-P. Briand, S. Muller, M. Prato, A. Bianco, Functionalized carbon nanotube cellular uptake and internalisation mechanism is independent of functional group and cell type, Nat. Nanotechnol. 2 (2007) 108-113.
109. C.H.J. Choi, J.E. Zuckerman, P. Webster, M.E. Davis, Targeting kidney mesangium by nanoparticles of defined size, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 6656-6661.
110. A. Bendele, J. Seely, C. Richey, G. Sennello, G. Shopp, Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins, Toxicol. Sci. 42 (1998) 152-157.
111. E. Wisse, F. Jacobs, B. Topal, P. Frederik, B. De Geest, The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer, Gene Ther. 15 (2008) 1193-1199.
112. F. Jacobs, E. Wisse, B. De Geest, The role of the sinusoidal cells in hepatocyte-directed gene transfer, Am. J. Pathol. 176 (2010) 14-21.
113. W. Jiang, B.Y. Kim, J.T. Rutka, W.C. Chan, Nanoparticle-mediated cellular response is size-dependent, Nat. Nanotechnol. 3 (2008) 145-150.
114. J.A. Champion, A. Walker, S. Mitragotri, Role of particle size in phagocytosis of polymeric microspheres, Pharm. Res. 25 (2008) 1815-1821.
115. N. Doshi, S. Mitragotri, Macrophages recognize size and shape of their targets, PLoS One 5 (2010) e10051.
116. R.A. Petros, J.M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discovery 9 (2010) 615-627.
117. G.J. Cannon, J.A. Swanson, The macrophage capacity for phagocytosis, J. Cell Sci. 101 (1992) 907-913.
118. J.A. Champion, S. Mitragotri, Shape induced inhibition of phagocytosis of polymer particles, Pharm. Res. 26 (2009) 244-249.
119. J.A. Champion, S. Mitragotri, Role of target geometry in phagocytosis, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4930-4934.
120. S.E. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, J.M. DeSimone, The effect of particle design on cellular internalization pathways, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11613-11618.
121. G. Sharma, D.T. Valenta, Y. Altman, S. Harvey, H. Xie, S. Mitragotri, J.W. Smith, Polymer particle shape independently influences binding and internalization by macrophages, J. Control. Release 147 (2010) 408-412.
122. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko, D.E. Discher, Shape effects of filaments versus spherical particles in flow and drug delivery, Nat. Nanotechnol. 2 (2007) 249-255.
123. S.-Y. Lin, W.-H. Hsu, J.-M. Lo, H.-C. Tsai, G.-H. Hsiue, Novel geometry type of nanocarriers mitigated the phagocytosis for drug delivery, J. Control. Release 154 (2011) 84-92.
124. Arnida, M. Janat-Amsbury, A. Ray, C.M. Peterson, H. Ghandehari, Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages, Eur. J. Pharm. Biopharm. 77 (2011) 417-423.
125. P. Decuzzi, B. Godin, T. Tanaka, S. Lee, C. Chiappini, X. Liu, M. Ferrari, Size and shape effect in the biodistribution of intravascularly injected particles, J. Control. Release 141 (2010) 320-327.
126. N. Doshi, B. Prabhakarpandian, A. Rea-Ramsey, K. Pant, S. Sundaram, S. Mitragotri, Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks, J. Control. Release 146 (2010) 196-200.
127. Z. Liu, W. Cai, L. He, N. Nakayama, K. Chen, X. Sun, X. Chen, H. Dai, In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice, Nat. Nanotechnol. 2 (2007) 47-52.
128. K.A. Beningo, Y.-L. Wang, Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target, J. Cell Sci. 115 (2002) 849-856.
129. X. Banquy, F. Suarez, A. Argaw, J.M. Rabanel, P. Grutter, J.F. Bouchard, P. Hildgen, S. Giasson, Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake, Soft Matter 5 (2009) 3984-3991.
130. J.-O. You, D.T. Auguste, Nanocarrier cross-linking density and pH sensitivity regulate intracellular gene transfer, Nano Lett. 9 (2009) 4467-4473.
131. T.J. Merkel, S.W. Jones, K.P. Herlihy, F.R. Kersey, A.R. Shields, M.E. Napier, C.J. Luft, H. Wu, W.C. Zamboni, A.Z. Wang, J.E. Bear, J.M. DeSimone, Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 586-591.
132. H. Hillaireau, P. Couvreur, Nanocarriers' entry into the cell: relevance to drug delivery, Cell. Mol. Life Sci. 66 (2009) 2873-2896.
133. M. Lück, B. Paulke, W. Schröder, T. Blunk, B. Müller, Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics, J. Biomed. Mater. Res. 39 (1998) 478-485.
134. A. Raz, C. Bucana, W.E. Fogler, G. Poste, I.J. Fidler, Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages, Cancer Res. 41 (1981) 487-494.
135. A. Chonn, S.C. Semple, P.R. Cullis, Association of blood proteins with large unilamellar liposomes - relation to circulation lifetimes, J. Biol. Chem. 267 (1992) 18759-18765.
136. K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, A.M. Gonik, R.G. Agarwal, K.S. Lam, The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles, Biomaterials 32 (2011) 3435-3446.
137. C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, Biomaterials 31 (2010) 3657-3666.
138. A. Mori, A.M. Klibanov, V.P. Torchilin, L. Huang, Influence of the steric barrier activity of amphiphatic poly(ethylene glycol) and ganglioside GM1 on the circulation time of the liposomes and on the target binding of immunoliposomes in vivo, FEBS Lett. 284 (1991) 263-266.
139. A. Gabizon, D. Papahadjopoulos, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6949-6953.
140. D. Peer, R. Margalit, Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mous tumor models, Neoplasia 6 (2004) 343-353.
141. D. Liu, F. Liu, Y.K. Song, Monosialoganglioside GM1 shortens the blood circulation time of liposomes in rats, Pharm. Res. 12 (1995) 508-551.
142. D. Liu, Q. Hu, y.K. Song, Liposome clearance from blood: different animal species have different mechanisms, Biochim. Biophys. Acta 1240 (1995) 277-284.
143. D. Liu, Y.K. Song, F. Liu, Antibody dependent, complement mediated liver uptake of liposomes containing GM1, Pharm. Res. 12 (1995) 1775-1780.
144. A. Rigotti, S.L. Acton, M. Krieger, The class B scavenger receptors SR-Bi and CD36 are receptors for anionic phospholipids, J. Biol. Chem. 270 (1995) 16221-16224.
145. V. Terpstra, T.J.C. Van Berkel, Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice, Blood 95 (2000) 2157-2163.
146. C.D. Oja, S.C. Semple, A. Chonn, P.R. Cullis, Influence of dose on liposome clearance: critical role of blood proteins, Biochim. Biophys. Acta 1281 (1996) 31-37.
147. T.M. Allen, C. Hansen, Pharmacokinetics of stealth versus conventional liposomes: effect of dose, Biochim. Biophys. Acta 1068 (1991) 133-141.
148. Z. Panagi, A. Beletsi, G. Evangelatos, E. Livianou, D. Ithakissios, K. Avgoustakis, Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles, Int. J. Pharm. 221 (2001) 143-152.
149. D.D. Chow, H.E. Essien, M.M. Padki, K.L. Hwang, Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect, J. Pharmacol. Exp. Ther. 248 (1989) 506-513.
150. E.W. van Etten, M.T. ten Kate, S.V. Snijders, I.A. Bakker-Woudenberg, Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system, Antimicrob. Agents Chemother. 42 (1998) 1677-1681.
151. H. Harashima, K. Sakata, H. Kiwada, Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes, Pharm. Res. 10 (1993) 606-610.
152. A. Gabizon, D. Tzemach, L. Mak, M. Bronstein, A.T. Horowitz, Dose dependency of pharmacokinetics and therapeutic efficacy of PEGylated liposomal doxorubicin (DOXIL) in murine models, J. Drug Target. 10 (2002) 539-548.
153. M. Synnes, K. Prydz, T. Løvdal, A. Brech, T. Berg, Fluid phase endocytosis and galactosyl receptor-mediated endocytosis employ different early endosomes, Biochim. Biophys. Acta 1421 (1999) 317-328.
154. K.-i. Ogawara, M. Yoshida, K. Higaki, T. Kimura, K. Shiraishi, M. Nishikawa, Y. Takakura, M. Hashida, Hepatic uptake of polystyrene microspheres in rats: Effect of particle size on intrahepatic distribution, J. Control. Release 59 (1999) 15-22.
155. T.M. Allen, C. Hansen, F. Martin, C. Redemann, A. Yau-Young, Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta 1066 (1991) 29-36.
156. J. Wu, M.H. Nantz, M.A. Zern, Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications, Front. Biosci. 7 (2002) d717-d725.
157. P.C. Rensen, L.A. Sliedregt, M. Ferns, E. Kieviet, S.M. van Rossenberg, S.H. van Leeuwen, T.J.C. Van Berkel, E.A.L. Biessen, Determination of the upper size limit for uptake and processing of ligands by asialoglycoprotein receptor on hepatocytes in vitro and in vivo, J. Biol. Chem. 276 (2001) 37577-37584.
158. M.K. Bijsterbosch, E.T. Rump, R.L.A.D. Vrueh, R. Dorland, R. van Veghel, K.L. Tivel, E.A.L. Biessen, T.J.C. van Berkel, M. Manoharan, Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation, Nucleic Acids Res. 28 (2000) 2717-2725.
159. S. Kunjachan, S. Jose, C.A. Thomas, E. Joseph, F. Kiessling, T. Lammers, Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy, Fundam. Clin. Pharmacol. (2011) [Electronic publication ahead of print, Jun 1], doi:10.1111/j.1472-8206.2011.00955.x.
160. Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, Y. Kawano, R. Takimoto, K. Takada, K. Miyanishi, T. Matsunaga, T. Takayam, Y. Niitsu, Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone, Nat. Biotechnol. 26 (2008) 431-442.
161. A.F. Hofmann, Biliary secretion and excretion in health and disease: current concepts, Ann. Hepatol. 6 (2007) 15-27.
162. I. Ellinger, R. Fuchs, Receptor-mediated and fluid-phase transcytosis of horseradish peroxidase across rat hepatocytes, J. Biomed. Biotechnol. 2010 (2010) 850320.
163. S. Friman, B. Egestad, J. Sjövall, J. Svanvik, Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat, J. Hepatol. 17 (1993) 48-55.
164. J. Munniksma, M. Noteborn, T. Kooistra, S. Stienstra, J.M.W. Bouma, M. Gruber, A. Brouwer, D. Praaning-Van Dalen, D.L. Knook, Fluid endocytosis by rat liver and spleen, Biochem. J. 192 (1980) 613-621.
165. M. Hashida, R. Atsumi, K. Nishida, S. Nakane, Y. Takakura, H. Sezaki, Biliary Excretion of Mitomycin C Dextran Conjugates in Relation to Physicochemical Characteristics of Carrier Dextran, J. Pharmacobio-Dyn. 13 (1990) 441-447.
166. W.G. Hardison, P.J. Lowe, M. Shanahan, Effect of molecular charge on para- and transcellular access of horseradish peroxidase into rat bile, Hepatology 9 (1989) 866-871.
167. K.-i. Ogawara, M. Yoshida, K. Furumoto, Y. Takakura, M. Hashida, K. Higaki, T. Kimura, Uptake by hepatocytes and biliary excretion of intravenously administered polystyrene microspheres in rats, J. Drug Target. 7 (1999) 213-221.
168. K. Furumoto, K.-i. Ogawara, M. Yoshida, Y. Takakura, M. Hashida, K. Higaki, T. Kimura, Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver, Biochim. Biophys. Acta 1526 (2001) 221-226.
169. S.M. Moghimi, Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents, Adv. Drug Delivery Rev. 17 (1995) 103-115.
170. R.E. Mebius, G. Kraal, Structure and function of the spleen, Nat. Rev. Immunol. 5 (2005) 606-616.
171. M. Demoy, J.-P. Andreux, C. Weingarten, B. Gouritin, V. Guilloux, P. Couvreur, Spleen capture of nanoparticles: influence of animal species and surface characteristics, Pharm. Res. 16 (1999) 37-41.
172. (R) PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting, J. Control. Release 60 (1999) 121-128.
173. M. Cho, W.-S. Cho, M. Choi, S.J. Kim, B.S. Han, S.H. Kim, H.O. Kim, Y.Y. Sheen, J. Jeong, The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles, Toxicol. Lett. 189 (2009) 177-183.
174. P. Laverman, M.G. Carstens, O.C. Boerman, E.T.M. Dams, W.J.G. Oyen, N. Van Rooijen, F.H.M. Corstens, G. Storm, Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection, J. Pharmacol. Exp. Ther. 298 (2001) 607-612.
175. T. Tagami, K. Nakamura, T. Shimizu, T. Ishida, H. Kiwada, Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production, J. Control. Release 137 (2009) 234-240.
176. T. Ishihara, M. Takeda, H. Sakamoto, A. Kimoto, C. Kobayashi, N. Takasaki, K. Yuki, K.-I. Tanaka, M. Takenaka, R. Igarashi, T. Maeda, N. Yamakawa, Y. Okamoto, M. Otsuka, T. Ishida, H. Kiwada, Y. Mizushima, T. Mizushima, Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles, Pharm. Res. 26 (2009) 2270-2279.
177. A. Judge, K. McClintock, J.R. Phelps, I. MacLachlan, Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes, Mol. Ther. 13 (2006) 328-337.
178. T. Ishida, T. Ichikawa, M. Ichihara, Y. Sadsuka, H. Kiwada, Effect of physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice, J. Control. Release 95 (2004) 403-412.
179. M.F. Bachmann, G.T. Jennings, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol. 10 (2010) 787-796.
180. T. Ishida, K. Atobe, X.Y. Wang, H. Kiwada, Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin- encapsulation and high dose first injection, J. Control. Release 115 (2006) 251-258.
181. T. Ishida, M. Harada, X.Y. Wang, M. Ichihara, K. Irimura, H. Kiwada, Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes, J. Control. Release 105 (2005) 305-317.
182. Y. Yamamoto, Y. Nagasaki, Y. Kato, Y. Sugiyama, K. Kataoka, Long-circulating poly(ethylene glycol)-poly(D, L-lactide) block copolymer micelles with modulated surface charge, J. Control. Release 77 (2001) 27-38.
183. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V.P. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres, Science 263 (1994) 1600-1602.
184. S.D. Perrault, C. Walkey, T. Jennings, H.C. Fischer, W.C. Chan, Mediating tumor targeting efficiency of nanoparticles through design, Nano Lett. 9 (2009) 1909-1915.
185. R. Duncan, Polymer conjugates for tumour targeting and intracytoplasmic delivery, Pharm. Sci. Technol. Today 2 (1999) 441-449.
186. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F.J. Martin, A. Huang, Y. Barenholz, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54 (1994) 987-992.
187. P. Bailon, A. Palleroni, C.A. Schaffer, C.L. Spence, W.-J. Fung, J.E. Porter, G.K. Ehrlich, W. Pan, Z.-X. Xu, M.W. Modi, A. Farid, W. Berthold, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C, Bioconjugate Chem. 12 (2001) 195-202.
188. D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, G. Scambia, Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), Ann. Oncol. 18 (2007) 1159-1164.
189. Y.H. Bae, K. Park, Targeted drug delivery to tumors: myths, reality and possibility, J. Control. Release 153 (2011) 198-205.
190. A. Gabizon, H. Schmeeda, Y. Barenholz, Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies, Clin. Pharmacokinet. 42 (2003) 419-436.